Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
Aytu BioPharma (Nasdaq: AYTU) has announced it will report its fiscal 2024 full year and fourth quarter operational and financial results on September 26, 2024, after market close. The company has scheduled a conference call and webcast for the same day at 4:30 p.m. Eastern time to review the results and conduct a Q&A session.
Interested parties can access the conference call by dialing (888) 506-0062 (US) or +1 (973) 528-0011 (international) using the participant access code 216512. The webcast will be available live and archived at a specific URL and on the Investors section of Aytu's website. A teleconference replay will be accessible until October 10, 2024.
Aytu BioPharma (Nasdaq: AYTU) ha annunciato che riporterà i suoi risultati operativi e finanziari dell'intero anno fiscale 2024 e del quarto trimestre il 26 settembre 2024, dopo la chiusura del mercato. L'azienda ha programmato una conference call e webcast per lo stesso giorno alle 16:30 ora orientale per rivedere i risultati e condurre una sessione di domande e risposte.
Le parti interessate possono partecipare alla conference call componendo il numero (888) 506-0062 (USA) o +1 (973) 528-0011 (internazionale) utilizzando il codice di accesso per i partecipanti 216512. Il webcast sarà disponibile in diretta e archiviato a un URL specifico e nella sezione Investitori del sito web di Aytu. Una registrazione della teleconferenza sarà accessibile fino al 10 ottobre 2024.
Aytu BioPharma (Nasdaq: AYTU) ha anunciado que informará sobre sus resultados operativos y financieros del año fiscal 2024 y del cuarto trimestre el 26 de septiembre de 2024, después del cierre del mercado. La compañía ha programado una llamada y transmisión en vivo para el mismo día a las 4:30 p.m. hora del este para revisar los resultados y llevar a cabo una sesión de preguntas y respuestas.
Las partes interesadas pueden acceder a la llamada marcando el (888) 506-0062 (EE. UU.) o +1 (973) 528-0011 (internacional) utilizando el código de acceso para participantes 216512. La transmisión en vivo estará disponible en directo y archivada en una URL específica y en la sección de Inversores del sitio web de Aytu. La grabación de la teleconferencia estará accesible hasta el 10 de octubre de 2024.
Aytu BioPharma (Nasdaq: AYTU)는 2024 회계연도 전체 및 4분기 운영 및 재무 결과를 2024년 9월 26일 시장 마감 후 발표한다고 발표했습니다. 회사는 같은 날 오후 4시 30분 동부 표준시에 결과를 검토하고 질의응답 세션을 진행하기 위한 전화 회의 및 웹캐스트를 계획했습니다.
관심 있는 분들은 (888) 506-0062 (미국) 또는 +1 (973) 528-0011 (국제)로 전화를 걸어 참가자 접근 코드 216512를 사용하여 전화 회의에 접속할 수 있습니다. 웹캐스트는 실시간으로 제공되며 특정 URL과 Aytu의 투자자 섹션에서도 아카이브됩니다. 전화 회의 녹음은 2024년 10월 10일까지 접근할 수 있습니다.
Aytu BioPharma (Nasdaq: AYTU) a annoncé qu'il présentera ses résultats opérationnels et financiers pour l'exercice fiscal 2024 et le quatrième trimestre le 26 septembre 2024, après la fermeture du marché. La société a programmé une conférence téléphonique et un webcast pour le même jour à 16h30 heure de l'Est afin de passer en revue les résultats et de mener une session de questions-réponses.
Les parties intéressées peuvent accéder à la conférence téléphonique en composant le (888) 506-0062 (États-Unis) ou +1 (973) 528-0011 (international) en utilisant le code d'accès des participants 216512. Le webcast sera disponible en direct et archivé à une URL spécifique ainsi que dans la section Investisseurs du site Web d'Aytu. Un enregistrement de la téléconférence sera accessible jusqu'au 10 octobre 2024.
Aytu BioPharma (Nasdaq: AYTU) hat angekündigt, dass es seine operativen und finanziellen Ergebnisse für das Gesamtjahr 2024 und das vierte Quartal am 26. September 2024, nach Marktschluss, bekannt geben wird. Das Unternehmen hat für denselben Tag um 16:30 Uhr Eastern Time eine Konferenzschaltung und Webcast angesetzt, um die Ergebnisse zu überprüfen und eine Frage-und-Antwort-Runde durchzuführen.
Interessierte Parteien können an der Konferenzschaltung teilnehmen, indem sie (888) 506-0062 (USA) oder +1 (973) 528-0011 (international) anrufen und den Teilnehmerzugangscode 216512 verwenden. Der Webcast wird live verfügbar sein und an einer spezifischen URL sowie im Bereich für Investoren auf der Website von Aytu archiviert. Eine Aufzeichnung der Telefonkonferenz ist bis zum 10. Oktober 2024 zugänglich.
- None.
- None.
DENVER, CO / ACCESSWIRE / September 19, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its fiscal 2024 full year and fourth quarter, after the market close on Thursday, September 26, 2024. The Company has scheduled a conference call and webcast that same day, Thursday, September 26, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Thursday, September 26, 2024, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 216512.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster4.com/Webcast/Page/2142/51231, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until October 10, 2024, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 51231.
About Aytu BioPharma,Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Contacts for Investors
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on accesswire.com
FAQ
When will Aytu BioPharma (AYTU) report its fiscal 2024 full year and Q4 results?
What time is Aytu BioPharma's (AYTU) earnings call scheduled for September 26, 2024?
How can investors access Aytu BioPharma's (AYTU) Q4 2024 earnings call?
Until what date will the replay of Aytu BioPharma's (AYTU) Q4 2024 earnings call be available?
